

LABORATORY REPORT

Name :	File. No. :
DOB/Gender :	Referral Doctor :
ID :	Referral Clinic :
Request Date :	Clinic File No :
Insurance :	

MOLECULAR BIOLOGY/GENETICS

*HPV 40 Real Time PCR-Human Papilloma Virus Genotyping

Specimen Source : LBC

REAL TIME PCR(NAAT)

1. Oncogenic HPV High Risk

Type 16:	Not Detected	Type 18:	Not Detected	Type 26:	Not Detected
Type 31:	Not Detected	Type 33:	Not Detected	Type 35:	Not Detected
Type 39:	Not Detected	Type 45:	Not Detected	Type 51:	Not Detected
Type 52:	Not Detected	Type 53:	Not Detected	Type 56:	Not Detected
Type 58:	Not Detected	Type 59:	Not Detected	Type 66:	Not Detected
Type 68:	Not Detected	Type 69:	Not Detected	Type 70:	Not Detected
Type 73:	Not Detected	Type 82:	Not Detected		

2. Oncogenic HPV Low Risk

Type 6:	Not Detected	Type 11:	Not Detected
---------	--------------	----------	--------------

3. Other HPV Low Risk Group Screening

(Type 34, Type 40, Type 55, Type 61, Type 87, Type 67, Type 74, Type 30, Type 32, Type 83, Type 84, Type 42, Type 44, Type 54, Type 62, Type 81, Type 90, Type 43) : **Detected**

(*Anyone among the other HPV low risk (group screening) is detected. The significance of other HPV LOW RISK (Group screen) is very minimal & undetermined)

Remarks: Clinical significance: Detection is carried out by the specific amplification of each genotype in the sample, originating a variable fragment with limit of detection between 50 to 500 genomic pairs (copies) / mL of the sample. The detection of the product is amplified by REAL TIME PCR platform. Over 170 HPV types have been identified. High risks HPV genotypes are carcinogenic and may lead to the development of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (AIN), with genotypes 16, 18, 31, 33, 35, 39, 45, 52 and 58 having the highest worldwide contribution to cervical cancer. HPV-16 is the most carcinogenic and is associated with approximately 60% of cervical cancers, while HPV-18 account for approximately 10-15% of cervical cancers. Low risk HPV rarely develop cancer and type 6 and 11 are linked to 90% of genital warts. **Please note: Revised Format w.e.f 27/03/2018.**

----- End Of Report -----

These tests are accredited under ISO 15189:2022 unless specified by (*)
Sample processed on the same day of receipt unless specified otherwise.
Test results pertains only the sample tested and to be correlated with clinical history.
Reference range related to Age/Gender.

Patient Sample Collected On :	Received On :
Authenticated On :	Released On :
Printed On :	